Supernus Pharmaceuticals SUPN Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's deferred tax assets?
- Supernus Pharmaceuticals (SUPN) reported deferred tax assets of $30.82M in Q1 2026.
- How has Supernus Pharmaceuticals's deferred tax assets changed year-over-year?
- Supernus Pharmaceuticals's deferred tax assets increased by 3041.7% year-over-year, from $981K to $30.82M.
- What is the long-term trend for Supernus Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's deferred tax assets has grown at a 1.7% compound annual growth rate (CAGR), from $35.22M to $38.35M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.